,Gene_set,Term,Overlap,P-value,Adjusted P-value,Old P-value,Old Adjusted P-value,Odds Ratio,Combined Score,Genes,cluster,ordered_cluster
0,KEGG_2021_Human,Neuroactive ligand-receptor interaction,15/341,1.043647397452382e-14,1.5237252002804777e-12,0,0,23.147711184521,745.2051365925187,GABBR2;VIPR1;ADCYAP1R1;CCK;HTR2A;AGT;C3;GRM3;ADCYAP1;GRM5;CCKBR;GRM7;SST;CRH;VIP,1,1
1,KEGG_2021_Human,Calcium signaling pathway,12/240,1.4871825959901125e-12,1.085643295072782e-10,0,0,24.709273182957396,672.9357473705566,FGF7;GRM5;CCKBR;FGF9;GNAS;CALM3;ADCY1;HTR2A;CALM1;NGF;CALM2;FGFR3,1,1
2,KEGG_2021_Human,Circadian entrainment,8/97,1.975782632037236e-10,9.615475475914548e-09,0,0,38.80214948705422,867.0296200628992,ADCYAP1;ADCYAP1R1;GNAS;GNB3;CALM3;ADCY1;CALM1;CALM2,1,1
3,KEGG_2021_Human,cAMP signaling pathway,10/216,2.7701689206967847e-10,1.0111116560543266e-08,0,0,21.77846425419241,479.277413398441,GABBR2;ADCYAP1;ADCYAP1R1;SST;GNAS;CALM3;ADCY1;VIP;CALM1;CALM2,1,1
4,KEGG_2021_Human,Renin secretion,7/69,6.627052212973212e-10,1.9350992461881785e-08,0,0,47.76527110501029,1009.5042375995776,ADCYAP1;ADCYAP1R1;GNAS;CALM3;CALM1;CALM2;AGT,1,1
5,KEGG_2021_Human,Pathways in cancer,13/531,1.1527687336172388e-09,2.7607335017155757e-08,0,0,11.892080233543648,244.75208290639924,HSP90AA1;LAMA2;ADCY1;AGT;FGF7;FGF9;GNAS;GNB3;CALM3;ITGAV;CALM1;CALM2;FGFR3,1,1
6,KEGG_2021_Human,Gastric acid secretion,7/76,1.3236393501376044e-09,2.7607335017155757e-08,0,0,42.90440949737897,877.0897296081049,CCKBR;SST;GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
7,KEGG_2021_Human,Vascular smooth muscle contraction,8/133,2.488011273086011e-09,4.54062057338197e-08,0,0,27.57704347826087,546.3503772110832,RAMP2;GNAS;CALM3;ADCY1;CALM1;CALM2;RAMP1;AGT,1,1
8,KEGG_2021_Human,Fluid shear stress and atherosclerosis,8/139,3.5311066224822603e-09,5.7282396320267786e-08,0,0,26.306007301692667,511.95842602033446,HSP90AA1;BMPR2;GPC1;SDC2;CALM3;ITGAV;CALM1;CALM2,1,1
9,KEGG_2021_Human,Rap1 signaling pathway,9/210,4.615446278133658e-09,6.73855156607514e-08,0,0,19.64676616915423,377.097225707356,FGF7;FGF9;GNAS;CALM3;ADCY1;CALM1;NGF;CALM2;FGFR3,1,1
10,KEGG_2021_Human,Inflammatory mediator regulation of TRP channels,7/98,8.005088723446983e-09,1.0624935942029632e-07,0,0,32.49590834697218,605.8273417710088,GNAS;CALM3;ADCY1;HTR2A;CALM1;NGF;CALM2,1,1
11,KEGG_2021_Human,Estrogen signaling pathway,7/137,8.212378823995972e-08,9.991727569195097e-07,0,0,22.70245499181669,370.3914185028143,GABBR2;HSP90AA1;GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
12,KEGG_2021_Human,Phospholipase D signaling pathway,7/148,1.394804664522445e-07,1.5664729309252071e-06,0,0,20.919722347970424,330.2249565556344,GRM3;GRM5;GRM7;GNAS;FYN;ADCY1;AGT,1,1
13,KEGG_2021_Human,Human cytomegalovirus infection,8/225,1.510122982568582e-07,1.5748425389643786e-06,0,0,15.811660989781608,248.33643840956776,GNAS;GNB3;CALM3;ITGAV;CALR;ADCY1;CALM1;CALM2,1,1
14,KEGG_2021_Human,Ras signaling pathway,8/232,1.909307265771219e-07,1.858392405350653e-06,0,0,15.312111801242237,236.8991199689825,FGF7;FGF9;GNB3;CALM3;CALM1;NGF;CALM2;FGFR3,1,1
15,KEGG_2021_Human,Aldosterone synthesis and secretion,6/98,2.532060573247528e-07,2.3105052730883694e-06,0,0,26.97554347826087,409.7332084142577,GNAS;CALM3;ADCY1;CALM1;CALM2;AGT,1,1
16,KEGG_2021_Human,Glutamatergic synapse,6/114,6.207353827865036e-07,5.331021522754678e-06,0,0,22.96064814814815,328.16187122039463,GRM3;GRM5;GRM7;GNAS;GNB3;ADCY1,1,1
17,KEGG_2021_Human,Neurotrophin signaling pathway,6/119,7.994057250720134e-07,6.484068658917442e-06,0,0,21.9391592920354,308.01257217083014,BEX3;MAGED1;CALM3;CALM1;NGF;CALM2,1,1
18,KEGG_2021_Human,Long-term potentiation,5/67,1.0094723525645732e-06,7.756998077601457e-06,0,0,32.725477287689266,451.8106486722008,GRM5;CALM3;ADCY1;CALM1;CALM2,1,1
19,KEGG_2021_Human,Adrenergic signaling in cardiomyocytes,6/150,3.0899152241317856e-06,2.2556381136162035e-05,0,0,17.18923611111111,218.08614532374077,GNAS;CALM3;ADCY1;CALM1;CALM2;AGT,1,1
20,KEGG_2021_Human,Insulin secretion,5/86,3.5017796057616127e-06,2.434570583053312e-05,0,0,25.025195263290502,314.3724904232026,ADCYAP1;ADCYAP1R1;GNAS;CCK;ADCY1,1,1
21,KEGG_2021_Human,PI3K-Akt signaling pathway,8/354,4.553897510211456e-06,3.022131984049421e-05,0,0,9.851721538074893,121.17151599998832,HSP90AA1;FGF7;LAMA2;FGF9;GNB3;ITGAV;NGF;FGFR3,1,1
22,KEGG_2021_Human,Salivary secretion,5/93,5.15158695877854e-06,3.133882066590278e-05,0,0,23.02643784786642,280.37464477370924,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
23,KEGG_2021_Human,GnRH signaling pathway,5/93,5.15158695877854e-06,3.133882066590278e-05,0,0,23.02643784786642,280.37464477370924,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
24,KEGG_2021_Human,Dilated cardiomyopathy,5/96,6.021867675296783e-06,3.5167707223733214e-05,0,0,22.26396052926665,267.6153236534291,LAMA2;GNAS;ITGAV;ADCY1;AGT,1,1
25,KEGG_2021_Human,Melanogenesis,5/101,7.724339574079212e-06,4.337513760829096e-05,0,0,21.09906462585034,248.3599218565523,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
26,KEGG_2021_Human,Alcoholism,6/186,1.0638466501721174e-05,5.752652256486265e-05,0,0,13.72638888888889,157.1813487493952,CRH;GNAS;GNB3;CALM3;CALM1;CALM2,1,1
27,KEGG_2021_Human,Dopaminergic synapse,5/132,2.831603443040529e-05,0.00014764789381568473,0,0,15.923991643901656,166.7573514553601,GNAS;GNB3;CALM3;CALM1;CALM2,1,1
28,KEGG_2021_Human,Apelin signaling pathway,5/137,3.3850551550368565e-05,0.0001704200181501314,0,0,15.316944959802102,157.66581943137734,GNB3;CALM3;ADCY1;CALM1;CALM2,1,1
29,KEGG_2021_Human,Amphetamine addiction,4/69,3.602036909984236e-05,0.00017529912961923282,0,0,24.46892307692308,250.35197505624168,GNAS;CALM3;CALM1;CALM2,1,1
30,KEGG_2021_Human,Pertussis,4/76,5.271485603870497e-05,0.0002482699671500299,0,0,22.08222222222222,217.52343067641664,C3;CALM3;CALM1;CALM2,1,1
31,KEGG_2021_Human,Phototransduction,3/28,5.810403466594087e-05,0.0002617739640180578,0,0,46.87294117647059,457.1647065883405,CALM3;CALM1;CALM2,1,1
32,KEGG_2021_Human,Oxytocin signaling pathway,5/154,5.916808775750622e-05,0.0002617739640180578,0,0,13.55773181755924,131.98625761046438,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
33,KEGG_2021_Human,Gap junction,4/88,9.354594936602666e-05,0.0004016973119835262,0,0,18.91619047619048,175.48659250397716,GRM5;GNAS;ADCY1;HTR2A,1,1
34,KEGG_2021_Human,Morphine addiction,4/91,0.000106577031711311,0.0004445784751386116,0,0,18.26114942528736,167.02820601322307,GABBR2;GNAS;GNB3;ADCY1,1,1
35,KEGG_2021_Human,Chagas disease,4/102,0.0001657823674426373,0.0006723396012951402,0,0,16.202448979591836,141.03963960469565,C3;GNAS;CALR;ADCY1,1,1
36,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,5/193,0.00017122135089338915,0.0006756301954171573,0,0,10.72405557967868,93.00494455997634,C3;GNB3;CALM3;CALM1;CALM2,1,1
37,KEGG_2021_Human,Glucagon signaling pathway,4/107,0.000199326791310776,0.0007658345139835076,0,0,15.412038834951456,131.31927733074235,GNAS;CALM3;CALM1;CALM2,1,1
38,KEGG_2021_Human,Serotonergic synapse,4/113,0.00024573837221964146,0.0009199436498478884,0,0,14.559266055045873,121.005599767331,APP;GNAS;GNB3;HTR2A,1,1
39,KEGG_2021_Human,Human immunodeficiency virus 1 infection,5/212,0.00026466355374569627,0.0009660219711717914,0,0,9.730355910480132,80.14943931431162,GNB3;CALM3;CALR;CALM1;CALM2,1,1
40,KEGG_2021_Human,Oocyte meiosis,4/129,0.000407000588894781,0.0014493191702106,0,0,12.68544,99.03137276252956,CALM3;ADCY1;CALM1;CALM2,1,1
41,KEGG_2021_Human,Chemical carcinogenesis,5/239,0.0004586521034758538,0.0015735975927782,0,0,8.595848595848596,66.07816703503416,HSP90AA1;FGF7;FGF9;GNAS;ADCY1,1,1
42,KEGG_2021_Human,Alzheimer disease,6/369,0.00046345682527030126,0.0015735975927782,0,0,6.743457300275482,51.76815497520017,APP;GRM5;CALM3;APOE;CALM1;CALM2,1,1
43,KEGG_2021_Human,Cortisol synthesis and secretion,3/65,0.0007219487708068914,0.0023955572849501,0,0,18.865275142314992,136.46303129351548,GNAS;ADCY1;AGT,1,1
44,KEGG_2021_Human,Cushing syndrome,4/155,0.0008119725925588695,0.0026343999669687,0,0,10.487417218543046,74.62892207334495,CRH;GNAS;ADCY1;AGT,1,1
45,KEGG_2021_Human,cGMP-PKG signaling pathway,4/167,0.001071387206826,0.0034004898303607,0,0,9.709447852760736,66.40098183251928,CALM3;ADCY1;CALM1;CALM2,1,1
46,KEGG_2021_Human,Glioma,3/75,0.0010950259740335,0.0034015700469979,0,0,16.236928104575163,110.68676861250448,CALM3;CALM1;CALM2,1,1
47,KEGG_2021_Human,Tuberculosis,4/180,0.0014128523783786,0.0042974259842351,0,0,8.986363636363636,58.96981810099653,C3;CALM3;CALM1;CALM2,1,1
48,KEGG_2021_Human,Axon guidance,4/182,0.0014713926415247,0.0043841495033187,0,0,8.884494382022472,57.9406383680362,BMPR2;FYN;SLIT2;L1CAM,1,1
49,KEGG_2021_Human,Pathways of neurodegeneration,6/475,0.0017113390889125,0.0049971101396246,0,0,5.191098081023454,33.06978194538061,APP;GRM5;CALM3;CALM1;CALM2;SPTBN2,1,1
50,KEGG_2021_Human,GABAergic synapse,3/89,0.0017932619219089,0.0051336517764451,0,0,13.584131326949384,85.9022295713123,GABBR2;GNB3;ADCY1,1,1
51,KEGG_2021_Human,Hypertrophic cardiomyopathy,3/90,0.001851578265349,0.0051986620527108,0,0,13.42731575388776,84.480869278287,LAMA2;ITGAV;AGT,1,1
52,KEGG_2021_Human,Phosphatidylinositol signaling system,3/97,0.0022930908485876,0.006316816299883,0,0,12.423028785982478,75.50536334754598,CALM3;CALM1;CALM2,1,1
53,KEGG_2021_Human,Amoebiasis,3/102,0.0026451820800154,0.0070217560669501,0,0,11.79263220439691,69.9894534650505,LAMA2;GNAS;ADCY1,1,1
54,KEGG_2021_Human,Pancreatic secretion,3/102,0.0026451820800154,0.0070217560669501,0,0,11.79263220439691,69.9894534650505,GNAS;CCK;ADCY1,1,1
55,KEGG_2021_Human,Lipid and atherosclerosis,4/215,0.002697650323824,0.007033159772827,0,0,7.482464454976303,44.261576705232,HSP90AA1;CALM3;CALM1;CALM2,1,1
56,KEGG_2021_Human,C-type lectin receptor signaling pathway,3/104,0.0027948406111328,0.0071378709283004,0,0,11.557949912638325,67.96051664386877,CALM3;CALM1;CALM2,1,1
57,KEGG_2021_Human,Regulation of actin cytoskeleton,4/218,0.0028355925605576,0.0071378709283004,0,0,7.376448598130841,43.26659132198892,FGF7;FGF9;ITGAV;FGFR3,1,1
58,KEGG_2021_Human,Cholinergic synapse,3/113,0.003532603766938,0.0087416974571687,0,0,10.607486631016044,59.88690015339679,GNB3;FYN;ADCY1,1,1
59,KEGG_2021_Human,"Growth hormone synthesis, secretion and action",3/119,0.0040846356940378,0.0099392801888255,0,0,10.05578093306288,55.31205165088091,SST;GNAS;ADCY1,1,1
60,KEGG_2021_Human,Parkinson disease,4/249,0.0045546647346007,0.0107913140441421,0,0,6.432979591836735,34.68407434869999,GNAS;CALM3;CALM1;CALM2,1,1
61,KEGG_2021_Human,Platelet activation,3/124,0.0045826128132658,0.0107913140441421,0,0,9.637822070977151,51.90435545086567,GNAS;FYN;ADCY1,1,1
62,KEGG_2021_Human,Relaxin signaling pathway,3/129,0.0051158757030462,0.011855838930869,0,0,9.253034547152197,48.813520364788914,GNAS;GNB3;ADCY1,1,1
63,KEGG_2021_Human,Insulin signaling pathway,3/137,0.0060441898254066,0.013788308039209,0,0,8.69710272168569,44.43052189846708,CALM3;CALM1;CALM2,1,1
64,KEGG_2021_Human,Cell adhesion molecules,3/148,0.0074756527592115,0.0165370500431042,0,0,8.032860040567952,39.32971687370552,SDC2;ITGAV;L1CAM,1,1
65,KEGG_2021_Human,Retrograde endocannabinoid signaling,3/148,0.0074756527592115,0.0165370500431042,0,0,8.032860040567952,39.32971687370552,GRM5;GNB3;ADCY1,1,1
66,KEGG_2021_Human,Cocaine addiction,2/49,0.0077582958785982,0.0169061372876917,0,0,16.28396072013093,79.12364418473429,GRM3;GNAS,1,1
67,KEGG_2021_Human,Phagosome,3/152,0.0080417151800258,0.0172007183947057,0,0,7.815633636004738,37.69568331530969,C3;ITGAV;CALR,1,1
68,KEGG_2021_Human,MAPK signaling pathway,4/294,0.0081291066385937,0.0172007183947057,0,0,5.422344827586207,26.09397303713418,FGF7;FGF9;NGF;FGFR3,1,1
69,KEGG_2021_Human,Ovarian steroidogenesis,2/51,0.0083825352441557,0.017483573509239,0,0,15.617739403453688,74.6778588702288,GNAS;ADCY1,1,1
70,KEGG_2021_Human,Cellular senescence,3/156,0.0086324665861653,0.0177512693180301,0,0,7.609765474817378,36.16331772907102,CALM3;CALM1;CALM2,1,1
71,KEGG_2021_Human,Regulation of lipolysis in adipocytes,2/55,0.0096962918823686,0.0196619252059142,0,0,14.436139332365748,66.92611152225938,GNAS;ADCY1,1,1
72,KEGG_2021_Human,Viral myocarditis,2/60,0.0114583775835129,0.0226070692863903,0,0,13.188328912466844,58.93909228909847,LAMA2;FYN,1,1
73,KEGG_2021_Human,Long-term depression,2/60,0.0114583775835129,0.0226070692863903,0,0,13.188328912466844,58.93909228909847,CRH;GNAS,1,1
74,KEGG_2021_Human,Melanoma,2/72,0.0162096794094039,0.0315548425836397,0,0,10.92087912087912,45.0174660560013,FGF7;FGF9,1,1
75,KEGG_2021_Human,Focal adhesion,3/201,0.0170388533623679,0.0327325340908647,0,0,5.8669043374925725,23.89155428844949,LAMA2;ITGAV;FYN,1,1
76,KEGG_2021_Human,Thyroid hormone synthesis,2/75,0.0175083669365894,0.0331976827628838,0,0,10.47049525816649,42.35395328238597,GNAS;ADCY1,1,1
77,KEGG_2021_Human,Proteoglycans in cancer,3/205,0.0179464602548854,0.033592092271965,0,0,5.749563191613279,23.115327578724173,GPC1;SDC2;ITGAV,1,1
78,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,2/77,0.0183979906866827,0.0340013498766541,0,0,10.19025641025641,40.71531033833909,LAMA2;ITGAV,1,1
79,KEGG_2021_Human,Antigen processing and presentation,2/78,0.0188498685675458,0.0344010101357711,0,0,10.055668016194332,39.933564949004506,HSP90AA1;CALR,1,1
80,KEGG_2021_Human,Taste transduction,2/86,0.0226308480405061,0.040791405110048,0,0,9.094322344322345,34.453306781873835,GABBR2;GNB3,1,1
81,KEGG_2021_Human,ECM-receptor interaction,2/88,0.0236211971779791,0.0420572535120117,0,0,8.881932021466906,33.268260367425945,LAMA2;ITGAV,1,1
82,KEGG_2021_Human,Bile secretion,2/90,0.0246291595740698,0.0433235819013758,0,0,8.679195804195805,32.14621536477304,GNAS;ADCY1,1,1
83,KEGG_2021_Human,Small cell lung cancer,2/92,0.0256545239983583,0.0445900059971466,0,0,8.485470085470086,31.082576873519034,LAMA2;ITGAV,1,1
84,KEGG_2021_Human,TGF-beta signaling pathway,2/94,0.0266970809068837,0.0458561624988827,0,0,8.300167224080267,30.07317459219205,BMPR2;RGMB,1,1
0,KEGG_2021_Human,ECM-receptor interaction,25/88,8.512913998541755e-42,8.683172278512589e-40,0,0,160.8600583090379,15212.051461369983,ITGB1;LAMA5;SDC4;LAMC3;LAMA1;LAMA4;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB2;FN1;HSPG2;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2;AGRN,2,2
1,KEGG_2021_Human,Focal adhesion,23/201,1.6311960241553826e-28,8.319099723192452e-27,0,0,50.0334875523243,3201.2960914209984,ITGB1;LAMA5;LAMB2;LAMC3;LAMA1;LAMA4;FN1;LAMC1;THBS2;THBS1;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;SPP1;COL4A5;COL6A3;ITGB8;COL9A3;ITGAV;COL9A2,2,2
2,KEGG_2021_Human,PI3K-Akt signaling pathway,26/354,3.4078798204561166e-27,1.15867913895508e-25,0,0,32.364583333333336,1972.4176892306607,ITGB1;LAMA5;LAMC3;LAMA1;LAMA4;LAMC1;FGF1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB2;FN1;VEGFA;COL1A1;EFNA1;COL1A2;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2;FGFR2,2,2
3,KEGG_2021_Human,Human papillomavirus infection,25/331,1.999140172409905e-26,5.097807439645258e-25,0,0,32.71308523409364,1935.7803065857288,ITGB1;LAMA5;LAMC3;LAMA1;LAMA4;LAMC1;PSEN1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB2;FN1;HLA-B;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2,2,2
4,KEGG_2021_Human,Protein digestion and absorption,15/103,2.3377768934873995e-20,4.769064862714294e-19,0,0,57.31317411402157,2590.698834709851,COL18A1;COL16A1;COL11A1;COL1A1;COL3A1;COL1A2;COL5A1;COL4A1;COL6A2;COL5A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2,2,2
5,KEGG_2021_Human,Amoebiasis,13/102,5.796429959590551e-17,9.853930931303934e-16,0,0,47.50064468594584,1775.89256059359,LAMA5;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;FN1;LAMC1;COL1A1;COL3A1;COL1A2;COL4A1;COL4A5,2,2
6,KEGG_2021_Human,Small cell lung cancer,11/92,3.47128757761169e-14,5.058161898805607e-13,0,0,42.77777777777778,1325.7545890029933,ITGB1;LAMA5;LAMB2;LAMC3;COL4A1;LAMA1;LAMA4;FN1;COL4A5;ITGAV;LAMC1,2,2
7,KEGG_2021_Human,Cell adhesion molecules,11/148,7.014035253204925e-12,8.942894947836279e-11,0,0,25.220600162206,647.7433962296824,ITGB1;VCAN;SDC4;SDC2;CNTN1;HLA-B;CNTN2;ITGB8;NCAM1;ITGAV;JAM3,2,2
8,KEGG_2021_Human,Axon guidance,11/182,6.645358541518154e-11,7.531406347053907e-10,0,0,20.17126148705096,472.70377780683873,EFNA1;EPHB6;ITGB1;CXCL12;BMPR2;SEMA4D;PLXNB2;PLXNB1;BMPR1B;BMP7;RGMA,2,2
9,KEGG_2021_Human,Pathways in cancer,16/531,7.915199472292509e-11,8.07350346173836e-10,0,0,10.397589554737197,241.84430561650245,ITGB1;LAMA5;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;FN1;LAMC1;FGF1;VEGFA;CXCL12;COL4A1;COL4A5;ITGAV;FGFR2,2,2
10,KEGG_2021_Human,Proteoglycans in cancer,11/205,2.3838965202962896e-10,2.2105222279111044e-09,0,0,17.759122893143513,393.49092091856966,COL1A1;ITGB1;COL1A2;SDC4;LUM;SDC2;FN1;ITGAV;HSPG2;THBS1;VEGFA,2,2
11,KEGG_2021_Human,TGF-beta signaling pathway,8/94,2.0545455410296518e-09,1.746363709875204e-08,0,0,27.96335447498238,559.3568843433821,BMPR2;TGFB3;BMPR1B;BMP7;THBS1;BMP6;RGMA;FBN1,2,2
12,KEGG_2021_Human,AGE-RAGE signaling pathway in diabetic complications,8/100,3.374591381038146e-09,2.647756314353007e-08,0,0,26.131752305665348,509.75187251702727,COL1A1;COL3A1;COL1A2;TGFB3;COL4A1;FN1;COL4A5;VEGFA,2,2
13,KEGG_2021_Human,Toxoplasmosis,8/112,8.323885174285462e-09,6.064544912693694e-08,0,0,23.102564102564106,429.80326121703234,ITGB1;LAMA5;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;LAMC1,2,2
14,KEGG_2021_Human,Relaxin signaling pathway,6/129,8.28728606066355e-06,5.635354521251214e-05,0,0,14.205882352941176,166.2200180131203,COL1A1;COL3A1;COL1A2;COL4A1;COL4A5;VEGFA,2,2
15,KEGG_2021_Human,Fluid shear stress and atherosclerosis,6/139,1.2707324538688248e-05,8.100919393413757e-05,0,0,13.131136665192392,148.03166310391782,BMPR2;SDC4;SDC2;ITGAV;BMPR1B;VEGFA,2,2
16,KEGG_2021_Human,Regulation of actin cytoskeleton,7/218,1.6082634643536928e-05,9.649580786122155e-05,0,0,9.761972129871967,107.75040762248923,ITGB1;CXCL12;FN1;ITGB8;ITGAV;FGF1;FGFR2,2,2
17,KEGG_2021_Human,Hypertrophic cardiomyopathy,5/90,2.080231742456564e-05,0.00011338409155871566,0,0,16.914748508098892,182.3485356492097,ITGB1;TGFB3;LAMA1;ITGB8;ITGAV,2,2
18,KEGG_2021_Human,Phagosome,6/152,2.112056607466272e-05,0.00011338409155871566,0,0,11.954069298952458,128.68870347031458,ITGB1;CANX;HLA-B;ITGAV;THBS2;THBS1,2,2
19,KEGG_2021_Human,Dilated cardiomyopathy,5/96,2.843787993841187e-05,0.00014503318768590057,0,0,15.794712533842969,165.33571023632018,ITGB1;TGFB3;LAMA1;ITGB8;ITGAV,2,2
20,KEGG_2021_Human,Hippo signaling pathway,6/163,3.1320551417901843e-05,0.0001521283926012375,0,0,11.110340951667292,115.22796895082244,BMPR2;TGFB3;BMPR1B;FGF1;BMP7;BMP6,2,2
21,KEGG_2021_Human,Malaria,4/50,3.4954026436736424e-05,0.00016205957711577798,0,0,24.695652173913043,253.41386407327417,TGFB3;SDC2;THBS2;THBS1,2,2
22,KEGG_2021_Human,Rap1 signaling pathway,6/210,0.00012758222961047167,0.0005657994530551353,0,0,8.530276816608996,76.48885506565905,EFNA1;ITGB1;FGF1;THBS1;FGFR2;VEGFA,2,2
23,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,4/77,0.0001904856505531071,0.0008095640148507052,0,0,15.540508806262231,133.11896796529538,ITGB1;LAMA1;ITGB8;ITGAV,2,2
24,KEGG_2021_Human,Cytokine-cytokine receptor interaction,6/295,0.0007822107780738185,0.0031914199745411,0,0,5.995420313454101,42.88755763228116,CXCL12;BMPR2;TGFB3;BMPR1B;BMP7;BMP6,2,2
25,KEGG_2021_Human,Platelet activation,4/124,0.0011586106740959,0.0045453187983764,0,0,9.43142857142857,63.76149056819061,COL1A1;ITGB1;COL3A1;COL1A2,2,2
26,KEGG_2021_Human,MAPK signaling pathway,5/294,0.0046767610279076,0.0176677638832067,0,0,4.923775136653127,26.416789696327697,EFNA1;TGFB3;FGF1;FGFR2;VEGFA,2,2
27,KEGG_2021_Human,Rheumatoid arthritis,3/93,0.0049711193657684,0.018109077689585,0,0,9.312676056338027,49.39546042973084,CXCL12;TGFB3;VEGFA,2,2
28,KEGG_2021_Human,Diabetic cardiomyopathy,4/203,0.0068170294804697,0.0239771381726867,0,0,5.664608758076095,28.256946088166053,COL1A1;COL3A1;COL1A2;TGFB3,2,2
29,KEGG_2021_Human,Leukocyte transendothelial migration,3/114,0.0087172375821013,0.0296386077791446,0,0,7.542824514655501,35.77148986016245,ITGB1;CXCL12;JAM3,2,2
30,KEGG_2021_Human,Human cytomegalovirus infection,4/225,0.0097116981249697,0.0319546196369973,0,0,5.095022624434389,23.612495782530704,CXCL12;HLA-B;ITGAV;VEGFA,2,2
31,KEGG_2021_Human,Bladder cancer,2/41,0.0100885355513959,0.0321572070700744,0,0,14.164529914529917,65.1052163056749,THBS1;VEGFA,2,2
32,KEGG_2021_Human,Ras signaling pathway,4/232,0.0107772774344613,0.0333115847974261,0,0,4.936842105263158,22.36545133549633,EFNA1;FGF1;FGFR2;VEGFA,2,2
33,KEGG_2021_Human,Signaling pathways regulating pluripotency of stem cells,3/143,0.0160345254765073,0.0481035764295221,0,0,5.971629778672032,24.68081179761652,BMPR2;BMPR1B;FGFR2,2,2
0,KEGG_2021_Human,Axon guidance,16/182,6.143652096673225e-21,7.433819036974602e-19,0,0,54.47986230636833,2535.431097844656,EPHB6;SEMA4A;BMPR2;SEMA3A;L1CAM;RGMA;EFNB2;EFNA1;EFNA3;EFNB3;SLIT1;PLXNA2;PLXNB2;PLXNA1;PLXNB1;FYN,3,3
1,KEGG_2021_Human,Gastric acid secretion,8/76,1.6619950987241945e-11,1.0055070347281375e-09,0,0,54.39398084815321,1350.0813019282598,CHRM3;SST;GNAS;CALM3;ADCY1;SSTR2;CALM1;CALM2,3,3
2,KEGG_2021_Human,cAMP signaling pathway,10/216,1.5213993016225158e-10,6.136310516544148e-09,0,0,23.375562396400664,528.4331161006214,AFDN;RYR2;BDNF;SST;GNAS;CALM3;ADCY1;SSTR2;CALM1;CALM2,3,3
3,KEGG_2021_Human,Calcium signaling pathway,10/240,4.261440048805576e-10,1.2890856147636866e-08,0,0,20.910922587486745,451.1791635619605,CHRM3;NTRK2;RYR2;GRM5;GNAS;CALM3;ADCY1;CALM1;CALM2;FGFR2,3,3
4,KEGG_2021_Human,Rap1 signaling pathway,9/210,2.713239686625052e-09,6.566040041632625e-08,0,0,21.05330490405117,415.27901741432834,EFNA1;AFDN;EFNA3;GNAS;CALM3;ADCY1;CALM1;CALM2;FGFR2,3,3
5,KEGG_2021_Human,Ras signaling pathway,9/232,6.4860256675641745e-09,1.3080151762921086e-07,0,0,18.955156950672645,357.3732479355673,EFNA1;AFDN;NTRK2;EFNA3;BDNF;CALM3;CALM1;CALM2;FGFR2,3,3
6,KEGG_2021_Human,Salivary secretion,6/93,1.3063243917085897e-07,2.258075019953419e-06,0,0,30.439846743295018,482.4983051410993,CHRM3;GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
7,KEGG_2021_Human,Circadian entrainment,6/97,1.6804872346961786e-07,2.54173694247797e-06,0,0,29.095970695970696,453.8683925156941,RYR2;GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
8,KEGG_2021_Human,Neurotrophin signaling pathway,6/119,5.655858540441729e-07,7.603987593260548e-06,0,0,23.405309734513278,336.6948300317316,NTRK2;BEX3;BDNF;CALM3;CALM1;CALM2,3,3
9,KEGG_2021_Human,Long-term potentiation,5/67,7.556502457754822e-07,9.143367973883335e-06,0,0,34.86500701262272,491.4462332737665,GRM5;CALM3;ADCY1;CALM1;CALM2,3,3
10,KEGG_2021_Human,Adrenergic signaling in cardiomyocytes,6/150,2.194842311057381e-06,2.414326542163119e-05,0,0,18.33796296296296,238.9326611227857,RYR2;GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
11,KEGG_2021_Human,Oxytocin signaling pathway,6/154,2.557298478822763e-06,2.57860929947962e-05,0,0,17.838738738738737,229.70157432355884,RYR2;GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
12,KEGG_2021_Human,GnRH signaling pathway,5/93,3.868783762000668e-06,3.600944886169853e-05,0,0,24.531867588932805,305.7301262254058,GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
13,KEGG_2021_Human,Aldosterone synthesis and secretion,5/98,5.007138045333038e-06,4.03909135656865e-05,0,0,23.20710612435717,283.23451619766166,GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
14,KEGG_2021_Human,Inflammatory mediator regulation of TRP channels,5/98,5.007138045333038e-06,4.03909135656865e-05,0,0,23.20710612435717,283.23451619766166,GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
15,KEGG_2021_Human,Melanogenesis,5/101,5.806669643086923e-06,4.391293917584486e-05,0,0,22.47848731884058,271.01195794624465,GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
16,KEGG_2021_Human,Alcoholism,6/186,7.591650505747006e-06,5.403468889384633e-05,0,0,14.643703703703704,172.6267378009186,NTRK2;BDNF;GNAS;CALM3;CALM1;CALM2,3,3
17,KEGG_2021_Human,Glutamatergic synapse,5/114,1.0497195591783222e-05,7.056448147809833e-05,0,0,19.784603111288398,226.8186518465858,GRM5;GNAS;SLC17A7;ADCY1;SHANK1,3,3
18,KEGG_2021_Human,Vascular smooth muscle contraction,5/133,2.2160560400782075e-05,0.00013349805179754996,0,0,16.831691576086957,180.38854449241376,GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
19,KEGG_2021_Human,Neuroactive ligand-receptor interaction,7/341,2.3934952288052774e-05,0.00013349805179754996,0,0,9.34301850843767,99.41131204948388,CHRM3;CORT;VIPR1;GRM5;SST;CHRNA4;SSTR2,3,3
20,KEGG_2021_Human,Pathways of neurodegeneration,8/475,2.478769818344427e-05,0.00013349805179754996,0,0,7.761366465813455,82.31055700707526,CHRM3;RYR2;GRM5;BDNF;CALM3;CALM1;CALM2;SPTBN2,3,3
21,KEGG_2021_Human,Apelin signaling pathway,5/137,2.556074640415341e-05,0.00013349805179754996,0,0,16.3183465085639,172.55758373501786,RYR2;CALM3;ADCY1;CALM1;CALM2,3,3
22,KEGG_2021_Human,Estrogen signaling pathway,5/137,2.556074640415341e-05,0.00013349805179754996,0,0,16.3183465085639,172.55758373501786,GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
23,KEGG_2021_Human,Fluid shear stress and atherosclerosis,5/139,2.740612087918982e-05,0.00013349805179754996,0,0,16.073166774821544,168.84450512822406,BMPR2;GPC1;CALM3;CALM1;CALM2,3,3
24,KEGG_2021_Human,Amphetamine addiction,4/69,2.868553179120908e-05,0.00013349805179754996,0,0,26.03469721767594,272.2999619910236,GNAS;CALM3;CALM1;CALM2,3,3
25,KEGG_2021_Human,Renin secretion,4/69,2.868553179120908e-05,0.00013349805179754996,0,0,26.03469721767594,272.2999619910236,GNAS;CALM3;CALM1;CALM2,3,3
26,KEGG_2021_Human,Phospholipase D signaling pathway,5/148,3.702866760869487e-05,0.00016594328817229922,0,0,15.054727880814838,153.61570551961768,ARF1;GRM5;GNAS;FYN;ADCY1,3,3
27,KEGG_2021_Human,Alzheimer disease,7/369,3.9578734076575255e-05,0.0001710366722594859,0,0,8.608048719236564,87.26167160544453,CHRM3;GRM5;ADAM10;CALM3;APOE;CALM1;CALM2,3,3
28,KEGG_2021_Human,Phototransduction,3/28,4.892036785487742e-05,0.0002041160176013851,0,0,49.81,494.3800262044663,CALM3;CALM1;CALM2,3,3
29,KEGG_2021_Human,Insulin secretion,4/86,6.825078055362669e-05,0.00027527814823296096,0,0,20.61961598339388,197.78998958092387,CHRM3;RYR2;GNAS;ADCY1,3,3
30,KEGG_2021_Human,Pancreatic secretion,4/102,0.0001325437143235115,0.0005173480462304803,0,0,17.23925314806774,153.92236199865638,CHRM3;RYR2;GNAS;ADCY1,3,3
31,KEGG_2021_Human,Glucagon signaling pathway,4/107,0.0001594572631095374,0.0006029477761329384,0,0,16.39826482131791,143.38207573637712,GNAS;CALM3;CALM1;CALM2,3,3
32,KEGG_2021_Human,Cholinergic synapse,4/113,0.00019672555098134784,0.0007213270202649421,0,0,15.490923287136445,132.19490665993504,CHRM3;CHRNA4;FYN;ADCY1,3,3
33,KEGG_2021_Human,"Growth hormone synthesis, secretion and action",4/119,0.00023990497290512933,0.0008537794623976661,0,0,14.678260869565218,122.3472331202438,SST;GNAS;ADCY1;SSTR2,3,3
34,KEGG_2021_Human,Human cytomegalovirus infection,5/225,0.00026568316853071457,0.0009185046683490418,0,0,9.747529644268775,80.2534200870244,GNAS;CALM3;ADCY1;CALM1;CALM2,3,3
35,KEGG_2021_Human,Oocyte meiosis,4/129,0.0003264419862028404,0.0010972077869595,0,0,13.497191489361702,108.34544253042898,CALM3;ADCY1;CALM1;CALM2,3,3
36,KEGG_2021_Human,Dopaminergic synapse,4/132,0.00035626298267516605,0.0011650762406404,0,0,13.178856382978724,104.63802930927736,GNAS;CALM3;CALM1;CALM2,3,3
37,KEGG_2021_Human,Cell adhesion molecules,4/148,0.0005491437022377603,0.001703753537712,0,0,11.705082742316783,87.87181656756027,CNTN1;CNTN2;NCAM1;L1CAM,3,3
38,KEGG_2021_Human,Retrograde endocannabinoid signaling,4/148,0.0005491437022377603,0.001703753537712,0,0,11.705082742316783,87.87181656756027,RIMS1;GRM5;SLC17A7;ADCY1,3,3
39,KEGG_2021_Human,cGMP-PKG signaling pathway,4/167,0.000863187272534167,0.0026111414994158,0,0,10.330766218509334,72.88230449848443,CALM3;ADCY1;CALM1;CALM2,3,3
40,KEGG_2021_Human,MAPK signaling pathway,5/294,0.0008964062940188855,0.002645491745763,0,0,7.394313224010832,51.88675950890251,EFNA1;NTRK2;EFNA3;BDNF;FGFR2,3,3
41,KEGG_2021_Human,Glioma,3/75,0.000926798741435889,0.0026700630408033,0,0,17.25434027777778,120.50041514783926,CALM3;CALM1;CALM2,3,3
42,KEGG_2021_Human,Pertussis,3/76,0.0009631598881733862,0.0027102871271855,0,0,17.017123287671232,118.18887540441294,CALM3;CALM1;CALM2,3,3
43,KEGG_2021_Human,Gap junction,3/88,0.0014715123364968,0.0040466589253662,0,0,14.605882352941176,95.2517448144162,GRM5;GNAS;ADCY1,3,3
44,KEGG_2021_Human,TGF-beta signaling pathway,3/94,0.0017782858455118,0.0047816130512652,0,0,13.638736263736265,86.36191536485507,BMPR2;RGMB;RGMA,3,3
45,KEGG_2021_Human,Dilated cardiomyopathy,3/96,0.0018887419901292,0.0049682126262096,0,0,13.344086021505376,83.69202965543494,RYR2;GNAS;ADCY1,3,3
46,KEGG_2021_Human,Phosphatidylinositol signaling system,3/97,0.0019455397883127,0.0050087300933157,0,0,13.201462765957446,82.40637964942252,CALM3;CALM1;CALM2,3,3
47,KEGG_2021_Human,PI3K-Akt signaling pathway,5/354,0.0020350809618085,0.0051300999245589,0,0,6.104397657904572,37.83029327695501,EFNA1;NTRK2;EFNA3;BDNF;FGFR2,3,3
48,KEGG_2021_Human,Pathways in cancer,6/531,0.0022266273954097,0.0054984064253994,0,0,4.933079365079365,30.127633885451427,GNAS;CALM3;ADCY1;CALM1;CALM2;FGFR2,3,3
49,KEGG_2021_Human,C-type lectin receptor signaling pathway,3/104,0.0023730744285327,0.0057428401170493,0,0,12.282178217821782,74.22819075934467,CALM3;CALM1;CALM2,3,3
50,KEGG_2021_Human,Parkinson disease,4/249,0.0037049325325254,0.0087901340477565,0,0,6.844637429439861,38.31689792331356,GNAS;CALM3;CALM1;CALM2,3,3
51,KEGG_2021_Human,Platelet activation,3/124,0.0038996254037596,0.0090741283433638,0,0,10.241735537190085,56.80962456263433,GNAS;FYN;ADCY1,3,3
52,KEGG_2021_Human,Nicotine addiction,2/40,0.0046740595984819,0.010670966253138,0,0,21.386680988184747,114.75509786105276,CHRNA4;SLC17A7,3,3
53,KEGG_2021_Human,Insulin signaling pathway,3/137,0.0051507016536939,0.0115413870388327,0,0,9.242070895522389,48.69298109698855,CALM3;CALM1;CALM2,3,3
54,KEGG_2021_Human,Cocaine addiction,2/49,0.0069448554030986,0.015278681886817,0,0,17.283543204515848,85.89496010554357,BDNF;GNAS,3,3
55,KEGG_2021_Human,Vibrio cholerae infection,2/50,0.0072225026271421,0.0156057646050749,0,0,16.922619047619047,83.43788300609687,ARF1;GNAS,3,3
56,KEGG_2021_Human,Cellular senescence,3/156,0.0073716338926862,0.0156485561581584,0,0,8.086601307189543,39.70614967382036,CALM3;CALM1;CALM2,3,3
57,KEGG_2021_Human,Ovarian steroidogenesis,2/51,0.0075051203009533,0.0156572337312991,0,0,16.576426488962934,81.09469280568841,GNAS;ADCY1,3,3
58,KEGG_2021_Human,Regulation of lipolysis in adipocytes,2/55,0.0086847744196851,0.0178111475386763,0,0,15.322294955718135,72.72242891249378,GNAS;ADCY1,3,3
59,KEGG_2021_Human,Tuberculosis,3/180,0.01087971815415,0.0219407649442025,0,0,6.981638418079096,31.5629745514898,CALM3;CALM1;CALM2,3,3
60,KEGG_2021_Human,Cortisol synthesis and secretion,2/65,0.0119692083073164,0.0237422000850048,0,0,12.8837058632977,57.01578256302679,GNAS;ADCY1,3,3
61,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,3/193,0.013120566714187,0.0256062672970424,0,0,6.499671052631579,28.16680744331868,CALM3;CALM1;CALM2,3,3
62,KEGG_2021_Human,Adherens junction,2/71,0.0141617305863652,0.0271995143007966,0,0,11.75983436853002,50.06410777572769,AFDN;FYN,3,3
63,KEGG_2021_Human,Thyroid hormone synthesis,2/75,0.0157125715616093,0.0297065806086677,0,0,11.113223371540396,46.1564856237522,GNAS;ADCY1,3,3
64,KEGG_2021_Human,Human immunodeficiency virus 1 infection,3/212,0.0168379218668381,0.0310225932434209,0,0,5.90311004784689,24.109019739798107,CALM3;CALM1;CALM2,3,3
65,KEGG_2021_Human,Synaptic vesicle cycle,2/78,0.0169214144964114,0.0310225932434209,0,0,10.672932330827068,43.53676225433978,RIMS1;SLC17A7,3,3
66,KEGG_2021_Human,Lipid and atherosclerosis,3/215,0.0174734371816651,0.0315565059549475,0,0,5.818691037735849,23.548669875985063,CALM3;CALM1;CALM2,3,3
67,KEGG_2021_Human,Bile secretion,2/90,0.0221351857372417,0.0393876099147978,0,0,9.211966604823749,35.1029985464868,GNAS;ADCY1,3,3
68,KEGG_2021_Human,Morphine addiction,2/91,0.0225961945539436,0.0396252107395244,0,0,9.108002751662465,34.51909152088551,GNAS;ADCY1,3,3
69,KEGG_2021_Human,Chemical carcinogenesis,3/239,0.0230387531768434,0.0398241304914007,0,0,5.220603813559322,19.68469159013861,CHRNA4;GNAS;ADCY1,3,3
70,KEGG_2021_Human,Amoebiasis,2/102,0.0279247580309207,0.0469291072464084,0,0,8.101632653061225,28.989598979218883,GNAS;ADCY1,3,3
71,KEGG_2021_Human,Chagas disease,2/102,0.0279247580309207,0.0469291072464084,0,0,8.101632653061225,28.989598979218883,GNAS;ADCY1,3,3
72,KEGG_2021_Human,"Parathyroid hormone synthesis, secretion and action",2/106,0.0299759378394035,0.049686143542025,0,0,7.788461538461538,27.31694072931825,GNAS;ADCY1,3,3
0,KEGG_2021_Human,ECM-receptor interaction,27/88,2.2768998046963986e-42,3.597501691420309e-40,0,0,123.69129531286076,11860.233747961536,ITGB1;LAMA5;LAMA2;SDC4;LAMC3;LAMA1;LAMA4;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;FN1;HSPG2;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2;AGRN,4,4
1,KEGG_2021_Human,PI3K-Akt signaling pathway,31/354,1.3996831283516716e-30,1.1057496713978203e-28,0,0,28.04625479414075,1927.936208640229,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;LPAR1;LAMC1;FGF1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;INSR;FN1;VEGFD;VEGFA;COL1A1;EFNA1;COL1A2;COL4A1;COL6A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2;FGFR2,4,4
2,KEGG_2021_Human,Focal adhesion,26/201,4.415205206576103e-30,2.3253414087967474e-28,0,0,40.70650793650794,2751.454575720308,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;FN1;VEGFD;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2,4,4
3,KEGG_2021_Human,Human papillomavirus infection,27/331,9.828325413052532e-26,3.88218853815575e-24,0,0,24.51565974796145,1411.6593431244858,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;PSEN1;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;HLA-B;FN1;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2,4,4
4,KEGG_2021_Human,Amoebiasis,16/102,4.133632434693486e-20,1.306227849363142e-18,0,0,44.959727736812255,2006.6670855778948,LAMA5;LAMB3;LAMA2;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;FN1;LAMC1;COL1A1;COL3A1;COL1A2;COL4A1;COL4A5;CD14,4,4
5,KEGG_2021_Human,Protein digestion and absorption,15/103,2.1203629915660903e-18,5.583622544457371e-17,0,0,40.69140197152245,1655.934339870709,COL18A1;COL16A1;COL11A1;COL1A1;COL3A1;COL1A2;COL5A1;COL4A1;COL6A2;COL5A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2,4,4
6,KEGG_2021_Human,Pathways in cancer,24/531,6.657368449262178e-17,1.5026631642620345e-15,0,0,12.406844714537025,462.1329099955584,ITGB1;LAMA5;LAMB3;LAMA2;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;LPAR1;FN1;VEGFD;LAMC1;FGF1;VEGFA;CXCL12;CDH1;COL4A1;COL4A5;ITGAV;IL6ST;CALM1;CALM2;FGFR2,4,4
7,KEGG_2021_Human,Small cell lung cancer,13/92,6.692191697819557e-16,1.3217078603193623e-14,0,0,38.37661950856292,1340.895206087864,ITGB1;LAMA5;LAMA2;LAMB3;LAMC3;LAMA1;LAMB2;LAMA4;FN1;LAMC1;COL4A1;COL4A5;ITGAV,4,4
8,KEGG_2021_Human,Cell adhesion molecules,13/148,3.6628116599850027e-13,6.430269358640339e-12,0,0,22.39398692810457,641.2602166409531,ITGB1;SDC4;SDC2;HLA-B;PTPRF;VCAN;CDH1;CNTN1;CNTN2;ITGB8;NCAM1;ITGAV;JAM3,4,4
9,KEGG_2021_Human,Proteoglycans in cancer,13/205,2.354003379282438e-11,3.7193253392662515e-10,0,0,15.700367647058824,384.2243988591581,ITGB1;SDC4;LUM;SDC2;FN1;HSPG2;THBS1;VEGFA;COL1A1;COL1A2;PLAU;GPC1;ITGAV,4,4
10,KEGG_2021_Human,Axon guidance,12/182,9.210356208541639e-11,1.3229420735905262e-09,0,0,16.195896032831737,374.2565065390963,EFNA1;EPHB6;ITGB1;CXCL12;BMPR2;SEMA4D;SEMA4C;PLXNB2;PLXNB1;BMPR1B;BMP7;RGMA,4,4
11,KEGG_2021_Human,Toxoplasmosis,10/112,1.8692474425731967e-10,2.461175799388043e-09,0,0,22.058823529411764,494.1245959676503,ITGB1;LAMA5;LAMB3;LAMA2;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;LAMC1,4,4
12,KEGG_2021_Human,Rap1 signaling pathway,12/210,4.823328669454777e-10,5.862199459798882e-09,0,0,13.88583509513742,297.88430334830133,EFNA1;ITGB1;CDH1;INSR;LPAR1;VEGFD;CALM1;FGF1;CALM2;THBS1;FGFR2;VEGFA,4,4
13,KEGG_2021_Human,AGE-RAGE signaling pathway in diabetic complications,9/100,1.4745693307208463e-09,1.664156816099241e-08,0,0,22.014940116063716,447.6716028813316,COL1A1;COL3A1;COL1A2;TGFB3;COL4A1;FN1;COL4A5;VEGFD;VEGFA,4,4
14,KEGG_2021_Human,TGF-beta signaling pathway,8/94,1.956914169836125e-08,2.0612829255607187e-07,0,0,20.481653746770025,363.5352608768189,BMPR2;TGFB3;BMPR1B;THBS1;BMP7;BMP6;RGMA;FBN1,4,4
15,KEGG_2021_Human,Fluid shear stress and atherosclerosis,9/139,2.715972663000969e-08,2.6820230047134574e-07,0,0,15.380121002592912,267.94524867030947,BMPR2;SDC4;GPC1;SDC2;ITGAV;CALM1;BMPR1B;CALM2;VEGFA,4,4
16,KEGG_2021_Human,Relaxin signaling pathway,7/129,3.3513405404458477e-06,3.114775325826141e-05,0,0,12.471626733921816,157.2191989836582,COL1A1;COL3A1;COL1A2;COL4A1;COL4A5;VEGFD;VEGFA,4,4
17,KEGG_2021_Human,Hypertrophic cardiomyopathy,6/90,5.2968266716363146e-06,4.649436745102988e-05,0,0,15.38664596273292,186.9231707102,ITGB1;LAMA2;LAMA1;TGFB3;ITGB8;ITGAV,4,4
18,KEGG_2021_Human,Dilated cardiomyopathy,6/96,7.702658130215776e-06,6.405368339863646e-05,0,0,14.356521739130434,169.03289845270623,ITGB1;LAMA2;LAMA1;TGFB3;ITGB8;ITGAV,4,4
19,KEGG_2021_Human,Phagosome,7/152,9.89243362853338e-06,7.815022566541371e-05,0,0,10.481167108753317,120.78224856709762,ITGB1;CANX;HLA-B;ITGAV;CD14;THBS2;THBS1,4,4
20,KEGG_2021_Human,Regulation of actin cytoskeleton,8/218,1.1887736560489689e-05,8.944106555035098e-05,0,0,8.335238095238095,94.52162692577576,ITGB1;CXCL12;LPAR1;FN1;ITGB8;ITGAV;FGF1;FGFR2,4,4
21,KEGG_2021_Human,Hippo signaling pathway,7/163,1.5591230560633774e-05,0.00011197338311727892,0,0,9.736686390532544,107.77345326049569,BMPR2;TGFB3;CDH1;FGF1;BMPR1B;BMP7;BMP6,4,4
22,KEGG_2021_Human,Ras signaling pathway,8/232,1.8641005308314328e-05,0.0001280556016832028,0,0,7.8087301587301585,85.0382178853409,EFNA1;INSR;VEGFD;CALM1;FGF1;CALM2;FGFR2;VEGFA,4,4
23,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,5/77,3.80869617591243e-05,0.000250739164914235,0,0,14.807347670250897,150.6742177092219,ITGB1;LAMA2;LAMA1;ITGB8;ITGAV,4,4
24,KEGG_2021_Human,MAPK signaling pathway,8/294,9.930151751137563e-05,0.0006144690227469199,0,0,6.096658896658897,56.19503708224811,EFNA1;TGFB3;INSR;VEGFD;CD14;FGF1;FGFR2;VEGFA,4,4
25,KEGG_2021_Human,Cytokine-cytokine receptor interaction,8/295,0.00010166243205252782,0.0006144690227469199,0,0,6.075106465350368,55.8536341179727,CXCL12;BMPR2;TGFB3;EBI3;IL6ST;BMPR1B;BMP7;BMP6,4,4
26,KEGG_2021_Human,Malaria,4/50,0.00010500420008966352,0.0006144690227469199,0,0,18.368177613321,168.28024670225724,TGFB3;SDC2;THBS2;THBS1,4,4
27,KEGG_2021_Human,Pertussis,4/76,0.0005307514944075333,0.0029949548612996,0,0,11.71985815602837,88.3819893649847,ITGB1;CD14;CALM1;CALM2,4,4
28,KEGG_2021_Human,Human cytomegalovirus infection,6/225,0.0008438686216191026,0.0045976290419247,0,0,5.861524717093508,41.48502170542564,CXCL12;HLA-B;ITGAV;CALM1;CALM2;VEGFA,4,4
29,KEGG_2021_Human,Bladder cancer,3/41,0.0010624397330365,0.0055955159273256,0,0,16.50747922437673,113.02980343103926,CDH1;THBS1;VEGFA,4,4
30,KEGG_2021_Human,Calcium signaling pathway,6/240,0.0011771239289775,0.0059995348638209,0,0,5.481605351170568,36.97168036050781,VEGFD;CALM1;FGF1;CALM2;FGFR2;VEGFA,4,4
31,KEGG_2021_Human,Ovarian steroidogenesis,3/51,0.0020033934744922,0.0098917552803052,0,0,13.06184210526316,81.15208599441814,INSR;CGA;BMP6,4,4
32,KEGG_2021_Human,Alzheimer disease,7/369,0.0022600275587646,0.0108207380086306,0,0,4.152146196345091,25.29644526723836,APP;NCSTN;ADAM17;INSR;PSEN1;CALM1;CALM2,4,4
33,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,5/193,0.0026137500127285,0.0121462500591504,0,0,5.637725920841913,33.527382986318635,HLA-B;IL6ST;CALM1;CALM2;VEGFA,4,4
34,KEGG_2021_Human,Notch signaling pathway,3/59,0.0030402916735731,0.0135004804592958,0,0,11.191353383458647,64.86286634070352,ADAM17;NCSTN;PSEN1,4,4
35,KEGG_2021_Human,Viral myocarditis,3/60,0.0031890358570432,0.0135004804592958,0,0,10.994459833795014,63.19655803906566,LAMA2;LAMA1;HLA-B,4,4
36,KEGG_2021_Human,Platelet activation,4/124,0.0032457957703778,0.0135004804592958,0,0,7.014893617021277,40.198109408804186,COL1A1;ITGB1;COL3A1;COL1A2,4,4
37,KEGG_2021_Human,Diabetic cardiomyopathy,5/203,0.0032469509965395,0.0135004804592958,0,0,5.350276963180189,30.657295006523963,COL1A1;COL3A1;COL1A2;TGFB3;INSR,4,4
38,KEGG_2021_Human,Apelin signaling pathway,4/137,0.0046303435082548,0.0182288267002807,0,0,6.325067989121741,33.998026152786615,CDH1;SPP1;CALM1;CALM2,4,4
39,KEGG_2021_Human,Insulin signaling pathway,4/137,0.0046303435082548,0.0182288267002807,0,0,6.325067989121741,33.998026152786615,INSR;CALM1;CALM2;PTPRF,4,4
40,KEGG_2021_Human,Renin secretion,3/69,0.0047302651564019,0.0182288267002807,0,0,9.49090909090909,50.81218251342342,ADCYAP1R1;CALM1;CALM2,4,4
41,KEGG_2021_Human,Adherens junction,3/71,0.0051238990120564,0.0192756200929742,0,0,9.210835913312694,48.57647122513271,CDH1;INSR;PTPRF,4,4
42,KEGG_2021_Human,Signaling pathways regulating pluripotency of stem cells,4/143,0.0053856434370955,0.0197891084432814,0,0,6.0502066431960815,31.60639136382187,BMPR2;IL6ST;BMPR1B;FGFR2,4,4
43,KEGG_2021_Human,Gastric cancer,4/149,0.0062193254571713,0.0223330323234789,0,0,5.798092443140132,29.45485362014396,TGFB3;CDH1;FGF1;FGFR2,4,4
44,KEGG_2021_Human,Bacterial invasion of epithelial cells,3/77,0.0064208987539244,0.0225444889582234,0,0,8.461450924608819,42.71507268155537,ITGB1;CDH1;FN1,4,4
45,KEGG_2021_Human,Cellular senescence,4/156,0.0072955183282064,0.025058519475144,0,0,5.529115341545353,27.205984652373804,TGFB3;HLA-B;CALM1;CALM2,4,4
46,KEGG_2021_Human,Phototransduction,2/28,0.0082683209877426,0.0277956322566668,0,0,15.926282051282053,76.37167960516742,CALM1;CALM2,4,4
47,KEGG_2021_Human,GnRH signaling pathway,3/93,0.010768661875962,0.0347234403347349,0,0,6.951578947368421,31.49840392735093,CGA;CALM1;CALM2,4,4
48,KEGG_2021_Human,Rheumatoid arthritis,3/93,0.010768661875962,0.0347234403347349,0,0,6.951578947368421,31.49840392735093,CXCL12;TGFB3;VEGFA,4,4
49,KEGG_2021_Human,Tuberculosis,4/180,0.0118977395911452,0.037378461209644,0,0,4.769342359767892,21.13489638986635,TGFB3;CD14;CALM1;CALM2,4,4
50,KEGG_2021_Human,Circadian entrainment,3/97,0.0120651995043787,0.037378461209644,0,0,6.654423292273236,29.395449378417208,ADCYAP1R1;CALM1;CALM2,4,4
51,KEGG_2021_Human,Longevity regulating pathway,3/102,0.0138068662760688,0.0419516321465168,0,0,6.316746411483254,27.052030304096284,INSR;ADIPOQ;ADIPOR1,4,4
52,KEGG_2021_Human,NF-kappa B signaling pathway,3/104,0.0145414918712316,0.0433501078425394,0,0,6.191036998436686,26.19272487484042,CXCL12;PLAU;CD14,4,4
53,KEGG_2021_Human,HIF-1 signaling pathway,3/109,0.0164736536291714,0.0482006902483163,0,0,5.897517378351539,24.215164624597787,INSR;TIMP1;VEGFA,4,4
0,KEGG_2021_Human,cAMP signaling pathway,8/216,2.3182668095570313e-09,1.5517088450916017e-07,0,0,29.227810650887573,581.1203668273105,AFDN;RYR2;CHRM1;SST;CALM3;SSTR2;CALM1;GNAI2,5,5
1,KEGG_2021_Human,Gastric acid secretion,6/76,3.042566362924709e-09,1.5517088450916017e-07,0,0,60.9061224489796,1194.403441471852,CCKBR;SST;CALM3;SSTR2;CALM1;GNAI2,5,5
2,KEGG_2021_Human,Axon guidance,7/182,2.0121135246007983e-08,6.841185983642713e-07,0,0,29.32,519.5942354391702,EPHB6;EFNB2;EFNA3;EFNB3;SLIT1;EFNA5;GNAI2,5,5
3,KEGG_2021_Human,Neuroactive ligand-receptor interaction,8/341,8.115678987234583e-08,2.0694981417448187e-06,0,0,18.14091014091014,296.18451513190706,CORT;CHRM1;CCKBR;GRM7;SST;CCK;HTR2A;SSTR2,5,5
4,KEGG_2021_Human,Rap1 signaling pathway,6/210,1.3128363571909242e-06,2.678186168669485e-05,0,0,20.758403361344534,281.13771193255405,AFDN;EFNA3;CALM3;CALM1;EFNA5;GNAI2,5,5
5,KEGG_2021_Human,Calcium signaling pathway,6/240,2.8470750775313763e-06,4.84002763180334e-05,0,0,18.06959706959707,230.73463100699243,RYR2;CHRM1;CCKBR;CALM3;HTR2A;CALM1,5,5
6,KEGG_2021_Human,Circadian entrainment,4/97,2.156192450375415e-05,0.00031418804276898906,0,0,28.491756272401435,306.1319988629952,RYR2;CALM3;CALM1;GNAI2,5,5
7,KEGG_2021_Human,Ras signaling pathway,5/232,4.2536702839266205e-05,0.0005423429612006442,0,0,14.992404678717907,150.90070088070948,AFDN;EFNA3;CALM3;CALM1;EFNA5,5,5
8,KEGG_2021_Human,Apelin signaling pathway,4/137,8.330216171755053e-05,0.0009440911661322396,0,0,19.88270676691729,186.75898159502256,RYR2;CALM3;CALM1;GNAI2,5,5
9,KEGG_2021_Human,Adrenergic signaling in cardiomyocytes,4/150,0.00011831640265006712,0.0012068273070306,0,0,18.100456621004565,163.667010233747,RYR2;CALM3;CALM1;GNAI2,5,5
10,KEGG_2021_Human,Oxytocin signaling pathway,4/154,0.00013095986019441544,0.0012143550672573,0,0,17.61422222222222,157.48206206712229,RYR2;CALM3;CALM1;GNAI2,5,5
11,KEGG_2021_Human,Renin secretion,3/69,0.00021781120976074915,0.0018513952829663,0,0,29.17888563049853,246.0329170453741,CALM3;CALM1;GNAI2,5,5
12,KEGG_2021_Human,Pertussis,3/76,0.0002898863382919705,0.0022744928081369,0,0,26.3716305788776,214.82387360798796,CALM3;CALM1;GNAI2,5,5
13,KEGG_2021_Human,Inflammatory mediator regulation of TRP channels,3/98,0.00061138323017245,0.0044543635341135,0,0,20.242105263157896,149.787258825716,CALM3;HTR2A;CALM1,5,5
14,KEGG_2021_Human,Melanogenesis,3/101,0.0006675615246963304,0.004539418367935,0,0,19.61948650427913,143.45531136353546,CALM3;CALM1;GNAI2,5,5
15,KEGG_2021_Human,Glutamatergic synapse,3/114,0.0009488462149607304,0.0060488946203746,0,0,17.310374891020054,120.4847761001414,GRM7;SLC17A7;GNAI2,5,5
16,KEGG_2021_Human,Phototransduction,2/28,0.0010313326933724,0.0060872681366267,0,0,47.93269230769231,329.6284964283434,CALM3;CALM1,5,5
17,KEGG_2021_Human,"Growth hormone synthesis, secretion and action",3/119,0.0010742237888164,0.0060872681366267,0,0,16.560066740823135,113.20721509642836,SST;SSTR2;GNAI2,5,5
18,KEGG_2021_Human,Pathways of neurodegeneration,5/475,0.001165687153069,0.0062578994533179,0,0,7.151870873074102,48.306915132844615,RYR2;CHRM1;CALM3;CALM1;SPTBN2,5,5
19,KEGG_2021_Human,Dopaminergic synapse,3/132,0.0014478813510186,0.0071865350620781,0,0,14.881470367591898,97.2899032072714,CALM3;CALM1;GNAI2,5,5
20,KEGG_2021_Human,Vascular smooth muscle contraction,3/133,0.0014795807480749,0.0071865350620781,0,0,14.766253101736972,96.2168536717446,CALM3;CALM1;RAMP1,5,5
21,KEGG_2021_Human,Estrogen signaling pathway,3/137,0.0016107379396855,0.0074458361944115,0,0,14.32258064516129,92.10941640869986,CALM3;CALM1;GNAI2,5,5
22,KEGG_2021_Human,Fluid shear stress and atherosclerosis,3/139,0.0016789630634457,0.0074458361944115,0,0,14.110531309297912,90.16035312545598,GPC1;CALM3;CALM1,5,5
23,KEGG_2021_Human,Retrograde endocannabinoid signaling,3/148,0.0020083403688533,0.0085354465676265,0,0,13.228698553948831,82.15612575990296,RIMS1;SLC17A7;GNAI2,5,5
24,KEGG_2021_Human,cGMP-PKG signaling pathway,3/167,0.0028292712295989,0.0115434266167638,0,0,11.684893784421716,68.56387327669977,CALM3;CALM1;GNAI2,5,5
25,KEGG_2021_Human,PI3K-Akt signaling pathway,4/354,0.0029425128713717,0.0115437043415352,0,0,7.472761904761905,43.55492808172386,EFNA3;CHRM1;RXRA;EFNA5,5,5
26,KEGG_2021_Human,Alcoholism,3/186,0.0038312187912271,0.0144734932113026,0,0,10.461660497091486,58.21466625762973,CALM3;CALM1;GNAI2,5,5
27,KEGG_2021_Human,Human immunodeficiency virus 1 infection,3/212,0.005516219787448,0.0196779463065167,0,0,9.148171014045378,47.57106079957416,CALM3;CALM1;GNAI2,5,5
28,KEGG_2021_Human,Lipid and atherosclerosis,3/215,0.0057349974716297,0.0196779463065167,0,0,9.017346317711503,46.54003898276535,RXRA;CALM3;CALM1,5,5
29,KEGG_2021_Human,Long-term potentiation,2/67,0.0057876312666225,0.0196779463065167,0,0,19.13557692307692,98.58710806700374,CALM3;CALM1,5,5
30,KEGG_2021_Human,Amphetamine addiction,2/69,0.0061280045998061,0.0201631119090397,0,0,18.5625,94.57382315557096,CALM3;CALM1,5,5
31,KEGG_2021_Human,Human cytomegalovirus infection,3/225,0.0065017419275791,0.0207243023941584,0,0,8.606800348735833,43.34113669761136,CALM3;CALM1;GNAI2,5,5
32,KEGG_2021_Human,PPAR signaling pathway,2/74,0.0070180079073391,0.0216079360168135,0,0,17.26909722222222,85.64221723890843,RXRA;FABP5,5,5
33,KEGG_2021_Human,Glioma,2/75,0.0072026453389378,0.0216079360168135,0,0,17.03167808219178,84.02249521013059,CALM3;CALM1,5,5
34,KEGG_2021_Human,Synaptic vesicle cycle,2/78,0.0077696949613526,0.0226431110302276,0,0,16.356907894736842,79.45407878009898,RIMS1;SLC17A7,5,5
35,KEGG_2021_Human,Parkinson disease,3/249,0.0085829105594822,0.0243182465851997,0,0,7.757671125098348,36.91086110308495,CALM3;CALM1;GNAI2,5,5
36,KEGG_2021_Human,Insulin secretion,2/86,0.0093768492240238,0.0258496924554172,0,0,14.793154761904765,69.07680592717206,RYR2;CCK,5,5
37,KEGG_2021_Human,Gap junction,2/88,0.0097999117683402,0.0263050263255447,0,0,14.44767441860465,66.82601170344869,HTR2A;GNAI2,5,5
38,KEGG_2021_Human,Salivary secretion,2/93,0.0108941545377731,0.0277800940713214,0,0,13.650412087912088,61.693432126641376,CALM3;CALM1,5,5
39,KEGG_2021_Human,GnRH signaling pathway,2/93,0.0108941545377731,0.0277800940713214,0,0,13.650412087912088,61.693432126641376,CALM3;CALM1,5,5
40,KEGG_2021_Human,Phosphatidylinositol signaling system,2/97,0.0118067009357296,0.0287672715120932,0,0,13.073026315789471,58.032314670661705,CALM3;CALM1,5,5
41,KEGG_2021_Human,Aldosterone synthesis and secretion,2/98,0.0120399374455695,0.0287672715120932,0,0,12.936197916666666,57.17186348229599,CALM3;CALM1,5,5
42,KEGG_2021_Human,Pathways in cancer,4/531,0.0121273791668628,0.0287672715120932,0,0,4.918153067678684,21.700315835632185,RXRA;CALM3;CALM1;GNAI2,5,5
43,KEGG_2021_Human,Pancreatic secretion,2/102,0.0129930685283717,0.0301202952248617,0,0,12.41625,53.9279860105189,RYR2;CCK,5,5
44,KEGG_2021_Human,C-type lectin receptor signaling pathway,2/104,0.0134816456100267,0.0305583967160606,0,0,12.17156862745098,52.41596085236459,CALM3;CALM1,5,5
45,KEGG_2021_Human,"Parathyroid hormone synthesis, secretion and action",2/106,0.0139781549967819,0.0308807533337134,0,0,11.936298076923077,50.971090560576506,RXRA;GNAI2,5,5
46,KEGG_2021_Human,Glucagon signaling pathway,2/107,0.0142293667322012,0.0308807533337134,0,0,11.82202380952381,50.27253405896206,CALM3;CALM1,5,5
47,KEGG_2021_Human,Serotonergic synapse,2/113,0.0157775957885995,0.0327264870759941,0,0,11.179617117117116,46.38606860239311,HTR2A;GNAI2,5,5
48,KEGG_2021_Human,Cholinergic synapse,2/113,0.0157775957885995,0.0327264870759941,0,0,11.179617117117116,46.38606860239311,CHRM1;GNAI2,5,5
49,KEGG_2021_Human,Leukocyte transendothelial migration,2/114,0.0160423956254873,0.0327264870759941,0,0,11.079241071428571,45.78518901835009,AFDN;GNAI2,5,5
50,KEGG_2021_Human,Neurotrophin signaling pathway,2/119,0.0173949601513483,0.0347899203026967,0,0,10.603098290598291,42.95924542462105,CALM3;CALM1,5,5
51,KEGG_2021_Human,Oocyte meiosis,2/129,0.0202401977431191,0.0397019263422721,0,0,9.763287401574804,38.07764747187854,CALM3;CALM1,5,5
52,KEGG_2021_Human,Insulin signaling pathway,2/137,0.0226471950748822,0.043585167879962,0,0,9.18101851851852,34.77512078354398,CALM3;CALM1,5,5
53,KEGG_2021_Human,Alzheimer disease,3/369,0.0244338646414197,0.0461528554337929,0,0,5.182443151771549,19.23611586199622,CHRM1;CALM3;CALM1,5,5
